Olli Ritvos

Person

Nyaste publikationer

  1. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy

    Puolakkainen, T., Ma, H., Kainulainen, H., Pasternack, A., Rantalainen, T., Ritvos, O., Heikinheimo, K., Hulmi, J. & Kiviranta, R. 19 jan 2017 I : BMC Musculoskeletal Disorders. 18, 11 sidantal, 20

    Publikation: Bidrag till tidskriftA1 Vetenskaplig originalartikel

  2. Activin inhibition limits early innate immune response in rat kidney allografts-a pilot study

    Palin, N. K., Savikko, J., Pasternack, A., Rintala, J. M., Kalra, B., Mistry, S., Kumar, A., Roth, M-P., Helin, H. & Ritvos, O. jan 2017 I : Transplant International. 30, 1, s. 96-107 12 sidantal

    Publikation: Bidrag till tidskriftA1 Vetenskaplig originalartikel

  3. Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Mullerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors

    Haltia, U-M., Hallamaa, M., Tapper, J., Hynninen, J., Alfthan, H., Kalra, B., Ritvos, O., Heikinheimo, M., Unkila-Kallio, L., Perheentupa, A. & Farkkila, A. jan 2017 I : Gynecologic Oncology. 144, 1, s. 83-89 7 sidantal

    Publikation: Bidrag till tidskriftA1 Vetenskaplig originalartikel

Visa alla (96) »

ID: 15568